Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tommysdad who wrote (4063)	4/15/1998 11:00:00 PM
From: John F Beule	Read Replies (1) of 6136

Thanks for your insight, I guess I read to much into the featured article of "Online Investor", to summarize: Agouron has three anticancer drugs in development, one of which is in Phase II/III trials and could have a very broad indication profile (it might be useful in combination with other drugs in treating many kinds of cancer). The progress of these drugs in development will have to be monitored, but the rapid success with which Agouron brought Viracept to market appears to reflect a powerful drug discovery platform in the company's protein structure-based approach to drug design and use of computer-enabled combinatorial chemistry. Agouron took Viracept from initial design to FDA approval in a record 38 months. Transmitted: 04/14/98 22:54

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next